AU2012335277B2 - Compositions and methods for treatment of cytomegalovirus - Google Patents

Compositions and methods for treatment of cytomegalovirus Download PDF

Info

Publication number
AU2012335277B2
AU2012335277B2 AU2012335277A AU2012335277A AU2012335277B2 AU 2012335277 B2 AU2012335277 B2 AU 2012335277B2 AU 2012335277 A AU2012335277 A AU 2012335277A AU 2012335277 A AU2012335277 A AU 2012335277A AU 2012335277 B2 AU2012335277 B2 AU 2012335277B2
Authority
AU
Australia
Prior art keywords
leu
ser
thr
val
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012335277A
Other languages
English (en)
Other versions
AU2012335277A1 (en
Inventor
David E. Anderson
Anne-Catherine Fluckiger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Variation Biotechnologies Inc
Original Assignee
Variation Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Variation Biotechnologies Inc filed Critical Variation Biotechnologies Inc
Publication of AU2012335277A1 publication Critical patent/AU2012335277A1/en
Priority to AU2018203538A priority Critical patent/AU2018203538A1/en
Application granted granted Critical
Publication of AU2012335277B2 publication Critical patent/AU2012335277B2/en
Priority to AU2020264275A priority patent/AU2020264275B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20241—Use of virus, viral particle or viral elements as a vector
    • C12N2760/20245—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
AU2012335277A 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus Active AU2012335277B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018203538A AU2018203538A1 (en) 2011-11-11 2018-05-18 Compositions and methods for treatment of cytomegalovirus
AU2020264275A AU2020264275B2 (en) 2011-11-11 2020-11-03 Compositions and methods for treatment of cytomegalovirus

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161558800P 2011-11-11 2011-11-11
US61/558,800 2011-11-11
US201261654157P 2012-06-01 2012-06-01
US61/654,157 2012-06-01
PCT/IB2012/002854 WO2013068847A2 (en) 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018203538A Division AU2018203538A1 (en) 2011-11-11 2018-05-18 Compositions and methods for treatment of cytomegalovirus

Publications (2)

Publication Number Publication Date
AU2012335277A1 AU2012335277A1 (en) 2014-06-12
AU2012335277B2 true AU2012335277B2 (en) 2018-06-14

Family

ID=48290708

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2012335277A Active AU2012335277B2 (en) 2011-11-11 2012-11-09 Compositions and methods for treatment of cytomegalovirus
AU2018203538A Abandoned AU2018203538A1 (en) 2011-11-11 2018-05-18 Compositions and methods for treatment of cytomegalovirus
AU2020264275A Active AU2020264275B2 (en) 2011-11-11 2020-11-03 Compositions and methods for treatment of cytomegalovirus

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018203538A Abandoned AU2018203538A1 (en) 2011-11-11 2018-05-18 Compositions and methods for treatment of cytomegalovirus
AU2020264275A Active AU2020264275B2 (en) 2011-11-11 2020-11-03 Compositions and methods for treatment of cytomegalovirus

Country Status (14)

Country Link
US (3) US9777043B2 (enExample)
EP (2) EP2776567B1 (enExample)
JP (2) JP6232544B2 (enExample)
KR (2) KR102301463B1 (enExample)
CN (3) CN111995664B (enExample)
AU (3) AU2012335277B2 (enExample)
BR (2) BR112014011229B1 (enExample)
CA (2) CA2889659C (enExample)
DK (1) DK2776567T3 (enExample)
ES (1) ES2874233T3 (enExample)
MX (2) MX353189B (enExample)
PT (1) PT2776567T (enExample)
RU (2) RU2737530C1 (enExample)
WO (1) WO2013068847A2 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3330368B1 (en) 2009-06-18 2021-07-21 Kiyatec Inc. Bioreactor system
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP4108671B1 (en) 2010-10-01 2024-11-20 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3682905T3 (pl) 2011-10-03 2022-04-04 Modernatx, Inc. Modyfikowane nukleozydy, nukleotydy i kwasy nukleinowe oraz ich zastosowania
WO2013068847A2 (en) 2011-11-11 2013-05-16 Variation Biotechnologies, Inc. Compositions and methods for treatment of cytomegalovirus
PL2791160T3 (pl) 2011-12-16 2022-06-20 Modernatx, Inc. Kompozycje zmodyfikowanego mrna
JP6265344B2 (ja) * 2012-03-27 2018-01-24 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 抗サイトメガロウイルス中和抗体の検出方法
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6294890B2 (ja) * 2012-10-30 2018-03-14 ファイザー・インク ヒトサイトメガロウイルス感染に対する組換え粒子ベースのワクチン
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
WO2015193143A1 (en) 2014-06-18 2015-12-23 Morphosys Ag Fusion proteins and uses thereof
KR101678740B1 (ko) * 2014-10-24 2016-11-23 단국대학교 천안캠퍼스 산학협력단 세포 부착활성 및 골분화 촉진활성을 나타내는 피브로넥틴 융합단백질
WO2016149426A1 (en) * 2015-03-16 2016-09-22 The Broad Institute, Inc. Constructs for continuous monitoring of live cells
US10968253B2 (en) 2015-10-20 2021-04-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methods and products for genetic engineering
CA3002922A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
WO2019209632A1 (en) * 2018-04-24 2019-10-31 Merck Sharp & Dohme Corp. Scalable chromatography process for purification of human cytomegalovirus
CA3099381A1 (en) 2018-05-04 2019-11-07 SpyBiotech Limited Vaccine composition
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
CA3130488A1 (en) 2019-03-19 2020-09-24 David R. Liu Methods and compositions for editing nucleotide sequences
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US20200376113A1 (en) * 2019-05-31 2020-12-03 Variation Biotechnologies Inc. Immunotherapeutic compositions for treatment of glioblastoma multiforme
US20220259617A1 (en) 2019-06-13 2022-08-18 The General Hospital Corporation Engineered human-endogenous virus-like particles and methods of use thereof for delivery to cells
GB201910651D0 (en) * 2019-07-25 2019-09-11 Autolus Ltd Virus-like particle
EP4028051A1 (en) * 2019-09-09 2022-07-20 GlaxoSmithKline Biologicals S.A. Immunotherapeutic compositions
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
MX2023001028A (es) 2020-07-24 2023-04-24 Massachusetts Gen Hospital Particulas similares a virus potenciadas y metodos de uso de las mismas para suministro a celulas.
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
CN115948468A (zh) * 2022-09-09 2023-04-11 青岛大学 一种人巨细胞病毒重组载体及其制备方法和应用
WO2024243675A1 (en) * 2023-06-02 2024-12-05 Variation Biotechnologies Inc. Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267965B1 (en) 1981-12-24 2001-07-31 Virogenetics Corporation Recombinant poxvirus—cytomegalovirus compositions and uses
JPS61103895A (ja) * 1984-10-26 1986-05-22 Green Cross Corp:The ＨＢｓＡｇの精製方法
EP0436537A4 (en) * 1988-01-29 1992-04-08 Chiron Corporation Recombinant cmv neutralizing proteins
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
DE19856463B4 (de) * 1998-11-26 2006-02-02 Heinrich-Pette-Institut Retrovirale, mit LCMV pseudotypisierte Hybrid-Vektoren
DE19910044A1 (de) 1999-03-08 2000-09-14 Bodo Plachter Virale Partikel, die nach Infektion durch humanes Cytomegalovirus freigesetzt werden und ihre Verwendung als Impfstoff
ATE345389T1 (de) * 1999-09-30 2006-12-15 Univ Washington Immunologisch relevante antigene aus herpes simplexvirus
EP1201750A1 (en) * 2000-10-26 2002-05-02 Genopoietic Synthetic viruses and uses thereof
US9045727B2 (en) * 2002-05-17 2015-06-02 Emory University Virus-like particles, methods of preparation, and immunogenic compositions
CA2756797C (en) 2002-12-23 2015-05-05 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
PT1651666E (pt) 2003-07-11 2009-08-28 Alphavax Inc Vacinas de citomegalovírus à base de alfavírus
RU2290204C1 (ru) * 2005-07-27 2006-12-27 Общество с ограниченной ответственностью "Аванген" Рекомбинантный гибридный белок, препарат для иммунотерапии на его основе и способ иммунотерапии рецидивирующего папилломатоза гортани
EP2044224A4 (en) * 2006-07-27 2011-04-13 Ligocyte Pharmaceuticals Inc CHIMERIC VIRUS TYPE PARTICLES
US20110250675A1 (en) 2008-03-26 2011-10-13 Life Technologies Corporaiton Virus-Like Particle Mediated Cellular Delivery
GB0907935D0 (en) * 2009-05-08 2009-06-24 Henderson Morley Plc Vaccines
WO2013068847A2 (en) 2011-11-11 2013-05-16 Variation Biotechnologies, Inc. Compositions and methods for treatment of cytomegalovirus
JP6679484B2 (ja) 2013-12-11 2020-04-15 ザ ヘンリー エム． ジャクソン ファウンデーション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド ヒトヘルペスウイルス三量体糖タンパク質Ｂ、三量体ｇＢを含むタンパク質複合体、及びワクチンとしてのそれらの使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090123494A1 (en) * 2007-07-31 2009-05-14 William Staplin Momlv-based pseudovirion packaging cell line

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GARRONE, P. et al., Science Translational Medicine, 2011, Vol. 3, 94ra71 *

Also Published As

Publication number Publication date
US12421283B2 (en) 2025-09-23
AU2012335277A1 (en) 2014-06-12
KR102301463B1 (ko) 2021-09-14
JP2015505299A (ja) 2015-02-19
AU2018203538A1 (en) 2018-06-07
BR122019027913B1 (pt) 2021-11-30
DK2776567T3 (da) 2021-04-26
MX2014005653A (es) 2014-09-04
KR20140095556A (ko) 2014-08-01
KR102340558B1 (ko) 2021-12-21
KR20190104644A (ko) 2019-09-10
CN111995664B (zh) 2024-08-02
WO2013068847A3 (en) 2014-10-30
WO2013068847A2 (en) 2013-05-16
US20170349634A1 (en) 2017-12-07
JP6232544B2 (ja) 2017-11-22
US20140308308A1 (en) 2014-10-16
AU2020264275B2 (en) 2023-12-14
CA3166278A1 (en) 2013-05-16
EP2776567A4 (en) 2015-12-30
ES2874233T3 (es) 2021-11-04
AU2020264275A1 (en) 2020-11-26
EP2776567A2 (en) 2014-09-17
CA2889659A1 (en) 2013-05-16
EP3854416A1 (en) 2021-07-28
CN107875382B (zh) 2024-03-08
US9777043B2 (en) 2017-10-03
CN104271745A (zh) 2015-01-07
MX387666B (es) 2025-03-18
EP2776567B1 (en) 2021-01-20
JP6657150B2 (ja) 2020-03-04
CN111995664A (zh) 2020-11-27
CA2889659C (en) 2023-03-14
BR112014011229B1 (pt) 2021-10-13
JP2018023374A (ja) 2018-02-15
PT2776567T (pt) 2021-05-25
MX353189B (es) 2018-01-05
RU2737530C1 (ru) 2020-12-03
US20230272013A1 (en) 2023-08-31
CN107875382A (zh) 2018-04-06
RU2019139064A (ru) 2020-01-27
US11248026B2 (en) 2022-02-15
BR112014011229A2 (pt) 2017-05-09

Similar Documents

Publication Publication Date Title
AU2020264275B2 (en) Compositions and methods for treatment of cytomegalovirus
KR101234981B1 (ko) 핵산 구조물
CN108368157B (zh) 人类免疫缺陷病毒抗原、载体、组合物、及其使用方法
JP2003529559A (ja) 新規用途
CN112972668A (zh) 重组修饰的痘苗病毒安卡拉(mva)丝状病毒疫苗
JP2010187681A (ja) ＨＩＶに対する免疫のためのｇｐ１２０と、Ｎｅｆ及び／又はＴａｔを含むワクチン
JP2007259870A (ja) Ｄｎａワクチン及び組換えウイルスベクターとして作用し得る二機能性プラスミド
EA021391B1 (ru) Способ индукции иммунного ответа, вакцинная композиция, ее применение и набор
JP2000517290A (ja) 保護的及び治療的な遺伝子免疫化のための方法及び組成物
JP2000506727A (ja) 組換え生ネコ免疫不全ウイルスおよびプロウイルスｄｎａワクチン
WO2015181142A1 (en) Cytomegalovirus complexes and uses thereof
Brown et al. Colocalization of human papillomavirus type 11 E1^ E4 and L1 proteins in human foreskin implants grown in athymic mice
JP2004518443A (ja) ヒト免疫不全ウイルスのキメラタンパク質用組換えポックスウイルス
CN110256539B (zh) O型口蹄疫病毒新型基因工程亚单位疫苗
HU211673A9 (en) Coccidiosis vaccines
CN114828881A (zh) 基孔肯雅病毒样颗粒疫苗及其使用方法
JP2005519959A (ja) Ｈｉｖに対する強化された免疫応答を誘導する方法
JP2006503800A (ja) Ｈｉｖに対する強化された免疫応答を誘導する方法
WO2013126469A1 (en) Chimeric dna vaccine compositions and methods of use
JP2939488B2 (ja) ＨＢｃもしくはＨＢｅ抗原とＨＩＶ中和エピトーからなる混成抗原粒子およびその製法
WO2004056391A1 (en) A method of immunisation and agents useful for same
CN118354790A (zh) 用于表达人乳头瘤病毒(hpv)抗原的慢病毒载体及其在治疗hpv诱发癌症中的应用
US20030118601A1 (en) FIV vaccine
WO2005103302A2 (en) Mutant viral nucleic acids and vaccine containing same

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ ANDERSON, DAVID E. AND FLUCKIGER, ANNE-CATHERINE

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME TO VARIATION BIOTECHNOLOGIES INC.

FGA Letters patent sealed or granted (standard patent)